LINE-1 as a therapeutic target for castration-resistant prostate cancer.

No abstract is available for this paper.

• Publication year

  2018

• Venue

  Frontiers in Bioscience

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.2741/4644PMID 28930600
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Prostate Cancer

  2018cited by this paper
• Transposable elements in cancer

  2017cited by this paper
• Custirsen in combination with docetaxel and prednisone for patients with metastatic castration-resistant prostate cancer (SYNERGY trial): a phase 3, multicentre, open-label, randomised trial.

  2017cited by this paper
• LINE-1 methylation status in prostate cancer and non-neoplastic tissue adjacent to tumor in association with mortality

  2017cited by this paper
• Abiraterone plus Prednisone in Metastatic, Castration‐Sensitive Prostate Cancer

  2017cited by this paper
• Gleason Grading, Biochemical Failure, and Prostate Cancer–Specific Death

  2017cited by this paper
• Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy

  2017cited by this paper
• Radium 223 dichloride for prostate cancer treatment

  2017cited by this paper
• Mechanisms of resistance to systemic therapy in metastatic castration-resistant prostate cancer.

  2017cited by this paper
• LINE-1 hypomethylation is associated to specific clinico-pathological features in Stage I non-small cell lung cancer.

  2017cited by this paper
• Hallmarks of response to immune checkpoint blockade

  2017cited by this paper
• The Human Long Interspersed Element-1 Retrotransposon: An Emerging Biomarker of Neoplasia.

  2017cited by this paper
• Revised Overall Survival Analysis of a Phase II, Randomized, Double-Blind, Controlled Study of PROSTVAC in Men With Metastatic Castration-Resistant Prostate Cancer.

  2017cited by this paper
• A comprehensive review of immunotherapies in prostate cancer.

  2017cited by this paper
• Exposure to pesticides and prostate cancer: systematic review of the literature

  2016cited by this paper
• Molecular mechanisms underlying resistance to androgen deprivation therapy in prostate cancer

  2016cited by this paper
• Phase 2 Study of the Safety and Antitumor Activity of Apalutamide (ARN-509), a Potent Androgen Receptor Antagonist, in the High-risk Nonmetastatic Castration-resistant Prostate Cancer Cohort

  2016cited by this paper
• The Reverse Transcriptase Encoded by LINE-1 Retrotransposons in the Genesis, Progression, and Therapy of Cancer

  2016cited by this paper
• Randomized, Double-Blind, Placebo-Controlled Phase III Study of Tasquinimod in Men With Metastatic Castration-Resistant Prostate Cancer.

  2016cited by this paper
• A phase I dose-escalation study of apatorsen (OGX-427), an antisense inhibitor targeting heat shock protein 27 (Hsp27), in patients with castration-resistant prostate cancer and other advanced cancers.

  2016cited by this paper
• Somatic retrotransposition is infrequent in glioblastomas

  2016cited by this paper
• Immunotherapy for prostate cancer: False promises or true hope?

  2016cited by this paper
• Involvement of retrotransposon L1 in stemness and cellular plasticity

  2015cited by this paper
• Functional screen identifies kinases driving prostate cancer visceral and bone metastasis

  2015cited by this paper
• Cancer statistics, 2015

  2015cited by this paper
• Targeting heat shock proteins in metastatic castration-resistant prostate cancer

  2015influential reference
• Enhanced expression of LINE-1-encoded ORF2 protein in early stages of colon and prostate transformation

  2015cited by this paper
• LINE-1 Methylation Level and Patient Prognosis in a Database of 208 Hepatocellular Carcinomas

  2015cited by this paper
• Efavirenz Has the Highest Anti-Proliferative Effect of Non-Nucleoside Reverse Transcriptase Inhibitors against Pancreatic Cancer Cells

  2015cited by this paper
• Mechanisms of resistance in castration-resistant prostate cancer (CRPC)

  2015cited by this paper
• Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial.

  2014cited by this paper
• Enzalutamide in metastatic prostate cancer before chemotherapy.

  2014cited by this paper
• Randomized, placebo-controlled, phase III trial of sunitinib plus prednisone versus prednisone alone in progressive, metastatic, castration-resistant prostate cancer.

  2014cited by this paper
• Tyrosine kinase inhibitors in the treatment of prostate cancer: taking the next step in clinical development

  2014cited by this paper
• A phase II trial evaluating the efficacy and safety of efavirenz in metastatic castration-resistant prostate cancer.

  2014cited by this paper
• Silencing of LINE-1 retrotransposons contributes to variation in small noncoding RNA expression in human cancer cells

  2014cited by this paper
• Long interspersed element-1 protein expression is a hallmark of many human cancers.

  2014cited by this paper
• The genetic epidemiology of prostate cancer and its clinical implications

  2014cited by this paper
• Molecular alterations and emerging targets in castration resistant prostate cancer.

  2014cited by this paper
• A tumor-promoting mechanism mediated by retrotransposon-encoded reverse transcriptase is active in human transformed cell lines

  2013cited by this paper
• In vitro evaluation of the therapeutic potential of nevirapine in treatment of human thyroid anaplastic carcinoma.

  2013cited by this paper
• High predictive value of CYP2B6 SNPs for steady-state plasma efavirenz levels in South African HIV/AIDS patients

  2013cited by this paper
• Inhibition of LINE-1 retrotransposon-encoded reverse transcriptase modulates the expression of cell differentiation genes in breast cancer cells

  2013cited by this paper
• Oncology meets immunology: the cancer-immunity cycle.

  2013cited by this paper
• LINE-1 ORF-1p functions as a novel androgen receptor co-activator and promotes the growth of human prostatic carcinoma cells.

  2013cited by this paper
• Abiraterone in metastatic prostate cancer without previous chemotherapy.

  2013cited by this paper
• Targeting the PI3K/Akt/mTOR pathway in castration-resistant prostate cancer.

  2013cited by this paper
• LINE-1 Hypomethylation Is Associated With a Poor Prognosis Among Patients With Curatively Resected Esophageal Squamous Cell Carcinoma

  2013cited by this paper
• L1 retrotransposons, cancer stem cells and oncogenesis

  2013cited by this paper
• Adverse events associated with nevirapine and efavirenz-based first-line antiretroviral therapy: a systematic review and meta-analysis

  2013cited by this paper
• Alpha emitter radium-223 and survival in metastatic prostate cancer.

  2013cited by this paper
• Long Interspersed Element–1 (LINE-1): Passenger or Driver in Human Neoplasms?

  2013cited by this paper
• The mitochondrial and autosomal mutation landscapes of prostate cancer.

  2013cited by this paper
• Punctuated evolution of prostate cancer genomes.

  2013cited by this paper
• Increased expression and copy number amplification of LINE-1 and SINE B1 retrotransposable elements in murine mammary carcinoma progression

  2013cited by this paper
• Epigenetic status of LINE-1 predicts clinical outcome in early-stage rectal cancer

  2013cited by this paper
• Progress of molecular targeted therapies for prostate cancers.

  2012cited by this paper
• The combined use of known antiviral reverse transcriptase inhibitors AZT and DDI induce anticancer effects at low concentrations.

  2012cited by this paper
• Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer

  2012cited by this paper
• Landscape of Somatic Retrotransposition in Human Cancers

  2012cited by this paper
• Increased survival with enzalutamide in prostate cancer after chemotherapy.

  2012cited by this paper
• Human transposon tectonics.

  2012cited by this paper
• Intermittent hormonal therapy in the treatment of metastatic prostate cancer: a randomized trial

  2012cited by this paper
• Extensive somatic L1 retrotransposition in colorectal tumors

  2012cited by this paper
• Hypomethylation of LINE-1 in primary tumor has poor prognosis in young breast cancer patients: a retrospective cohort study

  2012cited by this paper
• Effect of reverse transcriptase inhibitors on LINE-1 and Ty1 reverse transcriptase activities and on LINE-1 retrotransposition

  2011cited by this paper
• Retrotransposon-Encoded Reverse Transcriptase in the Genesis, Progression and Cellular Plasticity of Human Cancer

  2011cited by this paper
• Reciprocal feedback regulation of PI3K and androgen receptor signaling in PTEN-deficient prostate cancer.

  2011cited by this paper
• Mobile DNA and the TE-Thrust hypothesis: supporting evidence from the primates

  2011cited by this paper
• Abiraterone and increased survival in metastatic prostate cancer.

  2011cited by this paper
• LINE-1 elements in structural variation and disease.

  2011cited by this paper
• Sipuleucel-T immunotherapy for castration-resistant prostate cancer.

  2010cited by this paper
• The genomic complexity of primary human prostate cancer

  2010cited by this paper
• Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.

  2010cited by this paper
• Long Interspersed Nuclear Element 1 Hypomethylation Is a Marker of Poor Prognosis in Stage IA Non–Small Cell Lung Cancer

  2010cited by this paper
• Regression of castrate-recurrent prostate cancer by a small-molecule inhibitor of the amino-terminus domain of the androgen receptor.

  2010cited by this paper
• Triggers for genomic rearrangements: insights into genomic, cellular and environmental influences

  2010cited by this paper
• The Reverse Transcription Inhibitor Abacavir Shows Anticancer Activity in Prostate Cancer Cell Lines

  2010cited by this paper
• Natural mutagenesis of human genomes by endogenous retrotransposons.

  2010cited by this paper
• The relation between treatment outcome and efavirenz, atazanavir or lopinavir exposure in the NORTHIV trial of treatment-naïve HIV-1 infected patients

  2010cited by this paper
• Integrative genomic profiling of human prostate cancer.

  2010cited by this paper
• All y'all need to know 'bout retroelements in cancer.

  2010cited by this paper
• Association of nuclear localization of a long interspersed nuclear element-1 protein in breast tumors with poor prognostic outcomes.

  2010cited by this paper
• The antiretroviral nucleoside analogue Abacavir reduces cell growth and promotes differentiation of human medulloblastoma cells

  2009cited by this paper
• Nevirapine restores androgen signaling in hormone‐refractory human prostate carcinoma cells both in vitro and in vivo

  2009influential reference
• Nuclear receptor-induced chromosomal proximity and DNA breaks underlie specific translocations in cancer.

  2009cited by this paper
• The role of LHRH antagonists in the treatment of prostate cancer.

  2009cited by this paper
• Development of a Second-Generation Antiandrogen for Treatment of Advanced Prostate Cancer

  2009cited by this paper
• Pharmacogenetics‐Based Population Pharmacokinetic Analysis of Efavirenz in HIV‐1‐Infected Individuals

  2009cited by this paper
• L1 mobile element expression causes multiple types of toxicity.

  2008cited by this paper
• A cohort study of tumoral LINE-1 hypomethylation and prognosis in colon cancer.

  2008cited by this paper
• Nevirapine induces growth arrest and premature senescence in human cervical carcinoma cells.

  2008cited by this paper
• Nucleoside Analogue Reverse Transcriptase Inhibitors Differentially Inhibit Human LINE-1 Retrotransposition

  2008cited by this paper
• Expression of LINE-1 p40 protein in pediatric malignant germ cell tumors and its association with clinicopathological parameters: a report from the Children's Oncology Group.

  2007cited by this paper
• Hypomethylation of LINE-1 and Alu in well-differentiated neuroendocrine tumors (pancreatic endocrine tumors and carcinoid tumors)

  2007cited by this paper
• Intracellular Efavirenz Levels in Peripheral Blood Mononuclear Cells from Human Immunodeficiency Virus-Infected Individuals

  2007cited by this paper
• Differences in prognostic factors and survival among white and Asian men with prostate cancer, California, 1995-2004.

  2007cited by this paper
• Hypermethylation of CpG island loci and hypomethylation of LINE‐1 and Alu repeats in prostate adenocarcinoma and their relationship to clinicopathological features

  2007cited by this paper
• Regression of a cervical spinal mass following highly active antiretroviral therapy (HAART) in child with advanced human immunodeficiency virus (HIV) disease.

  2007cited by this paper
• Distinct roles for LINE-1 and HERV-K retroelements in cell proliferation, differentiation and tumor progression

  2007cited by this paper

• Exploring Potential for Repurposing Antiretroviral Drugs Etravirine and Efavirenz in Prostate and Bladder Cancer

  2025cites this paper
• LINE-1 266/97 and ALU 260/111 Copy Number Ratios in Circulating Cell-Free DNA in Plasma as Potential Biomarkers for the Detection of Prostate Cancer: A Pilot Case-Control Study

  2025cites this paper
• Reverse transcriptase inhibitors induce autophagy in a LINE-1 ORF1p-dependent manner

  2025cites this paper
• State‐of‐the‐art in transposable element modulation affected by drugs in malignant prostatic cancer cells

  2024cites this paper
• Efavirenz: New Hope in Cancer Therapy

  2024cites this paper
• Role of Transposable Elements in Genome Stability: Implications for Health and Disease

  2022cites this paper
• The promising role of new molecular biomarkers in prostate cancer: from coding and non-coding genes to artificial intelligence approaches

  2022cites this paper
• Integration of TE Induces Cancer Specific Alternative Splicing Events

  2022cites this paper
• An Epigenetic LINE-1-Based Mechanism in Cancer

  2022cites this paper
• Combination of Antiretroviral Drugs Zidovudine and Efavirenz Impairs Tumor Growths in a Mouse Model of Cancer

  2021cites this paper
• Reverse transcriptase inhibitors promote the remodeling of nuclear architecture and induce autophagy in prostate cancer cells.

  2020cites this paper
• Transposable Elements.

  2019cites this paper
• miR-425-5p suppresses tumorigenesis and DDP resistance in human-prostate cancer by targeting GSK3β and inactivating the Wnt/β-catenin signaling pathway

  2019cites this paper
• LINE-1 activity and regulation in cancer.

  2018cites this paper
• Establishment of a recombinant Escherichia coli-induced piglet diarrhea model.

  2018cites this paper
• Discovery of the Long Interspersed Nuclear Element-1 activation product [Open Reading Frame-1 (ORF1) protein] in human blood.

  2018cites this paper